Navigation Links
Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013
Date:10/31/2013

SAN FRANCISCO, CA October 31, 2013 Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Third-generation permanent polymer-based drug-eluting stents (DES) with novel flexible designs were developed to improve stent deliverability in challenging anatomical lesions and to improve stent alignment within the vessel wall, while maintaining the anti-restenotic potential of newer generation DES systems. DUTCH PEERS (TWENTE II) follows the TWENTE trial, which was presented at TCT 2011 and examined second-generation drug-eluting stents with the same drugs and coatings but different stent platforms.

DUTCH PEERS was a multicenter, prospective, single-blinded, randomized controlled study in patients requiring percutaneous coronary interventions (PCI) with DES implantation. The study was performed in four PCI centers in the Netherlands (Thoraxcentrum Twente, Enschede; Rijnstate Hospital, Arnhem; Scheper Hospital, Emmen; Medical Center Alkmaar, Alkmaar). The primary endpoint was the composite target vessel failure (TVF) at one-year, defined as cardiac death, target vessel revascularization, or myocardial infarction (MI) attributable to the target vessel or not attributable to another vessel.

A total of 1,811 patients were randomly assigned to treatment with third-generation cobalt-chromium zotarolimus-eluting stents (906 patients; 1,205 lesions) or platinum-chromium everolimus-eluting stents (905 patients; 1,166 lesions). The study population (age 63.910.8 years, range 21󈟇 years; 73.0 percent male) was an "all-comers" population comprising 58.6 percent of patients with acute coronary syndromes (20.4 percent of all patients presented with an acute ST-elevation myocardial infarction). Of all 2,371 lesions, 65.7 percent were ACC/AHA lesion type B2/C. Follow-up data for 99.9 percent of the randomized patients were obtained.

TVF occurred in 6.1 percent (55/905) patients assigned to zotarolimus-eluting stents and 5.2 percent (47/905) assigned to everolimus-eluting stents. Non-inferiority of the zotarolimus-eluting stent was confirmed with an absolute risk difference of 0.88 percent (non-inferiority p-value = 0.006). There was also no significant between-group difference in individual components of the primary endpoint and other secondary clinical endpoints.

In both stent groups, definite-or-probable stent thrombosis rates were low. Definite-or-probable stent thrombosis rates were 0.6 percent (5/905) in the zotarolimus stent and 0.9 percent (8/905) in the everolimus stent (p value=0.40). Notably, there was no definite stent thrombosis beyond three months from stenting, reaffirming the safety of newer generation DES platforms.

"The clinical outcome of this trial was excellent particularly when considering its high proportion of complex patients with acute myocardial infarction at presentation and may represent a challenging touchstone of novel stents and scaffolds," said Clemens von Birgelen, MD PhD, the principal investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.

"Both permanent polymer-based stents were similarly efficacious and safe in treating all-comers with an excellent clinical outcome."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. False-Positive Mammogram Results May Turn Out Not to Be: Study
2. Good intentions bring mixed results for Haitis disabled people
3. Presentation of 1-year IVAN and 2-year CATT study results
4. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
5. Surprising results for use of dialysis for kidney failure in developing world
6. Stem Cell Study Shows Promising Results Against Heart Failure
7. Automated insulin dosage titration system demonstrates positive clinical study results
8. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
9. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
10. ACP-New York State Chapter partnership results in patient safety organization recognition
11. Long-term testosterone treatment for men results in reduced weight and waist size
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Super-Sod will attend ... 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show ... , For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Social media ... especially for hospitals and health systems. Smith & Jones’ delves into this insight and ... episode, President of Smith & Jones David Vener meets up with social media strategist ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a ... Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, ... on Aging is a tremendous resource in our community. We are thrilled to participate ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017 Research and Markets has announced ... (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By Country ... ... forecasted to grow at a CAGR of 5.33% during 2016-2021 ... infectious diseases along with surging demand of digital thermometer. Apart from ...
(Date:2/22/2017)... Feb. 22, 2017 Oncternal Therapeutics, Inc., ... both rare and common malignancies, today announced the ... The company intends to use the proceeds to ... and to advance preclinical development of a new ... is a first-in-class anti-ROR1 monoclonal antibody being developed ...
(Date:2/22/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced that KCP-400 (RgIA4), a potent antagonist ... robust chronic pain relief and disease modifying effects ... the a9a10 nAChR as a new, non-opioid target ... were reported online in the February 20 th ...
Breaking Medicine Technology: